Holen Sie sich die Stockscreener-App
5.27
1.74%
0.09
Handel nachbörslich:
5.27
Schlusskurs vom Vortag:
$5.18
Offen:
$5.12
24-Stunden-Volumen:
353.19K
Relative Volume:
0.66
Marktkapitalisierung:
$313.15M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.54M
KGV:
-5.9213
EPS:
-0.89
Netto-Cashflow:
$-30.33M
1W Leistung:
-2.77%
1M Leistung:
-1.31%
6M Leistung:
+26.68%
1J Leistung:
+138.46%
1-Tages-Spanne:
$4.93
$5.275
1-Wochen-Bereich:
$4.93
$5.52
52-Wochen-Spanne:
$2.20
$6.5476
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Firmenname
Aldeyra Therapeutics Inc
Sektor
Branche
Telefon
781-761-4904
Adresse
131 HARTWELL AVENUE, LEXINGTON, MA
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-03 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-04-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-02-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-10-30 | Eingeleitet | Jefferies | Buy |
| 2020-10-16 | Eingeleitet | BTIG Research | Buy |
| 2020-09-22 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Outperform |
| 2018-12-04 | Eingeleitet | Citigroup | Buy |
| 2018-09-26 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Eingeleitet | Janney | Buy |
| 2018-01-26 | Eingeleitet | Seaport Global Securities | Buy |
| 2016-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-07-01 | Eingeleitet | Stifel | Buy |
| 2015-07-01 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2015-03-20 | Bestätigt | H.C. Wainwright | Buy |
| 2014-11-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2014-06-19 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Aldeyra Therapeutics Inc Aktie (ALDX) Neueste Nachrichten
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting - StockTitan
International Assets Investment Management LLC Buys 229,487 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
Short Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Increases By 13.3% - MarketBeat
(ALDX) Long Term Investment Analysis - Stock Traders Daily
Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, - openPR
Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, Clinical Trials, Therapies, and Key Companies Involved by DelveInsight | Ocular Therapeutix, Aldeyra Therapeutics, Aciex Therapeutics - Barchart
Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail
Allergic Conjunctivitis Pipeline 2024: Clinical Trials - openPR
(ALDX) Investment Analysis - Stock Traders Daily
Dimensional Fund Advisors LP Sells 210,153 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
Nephrotic Syndrome Drugs Market Set for Rapid Expansion with - openPR
(ALDX) Proactive Strategies - Stock Traders Daily
American Century Companies Inc. Acquires 36,528 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Renaissance Technologies LLC Sells 224,390 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
Lexington biotech resubmits dry eye drug for FDA approval a year after rejection - The Business Journals
Aldeyra Resubmits New Drug Application for Reproxalap for Dry Eye Disease - MD Magazine
Aldeyra Therapeutics stock affirmed at Outperform on NDA submission By Investing.com - Investing.com Canada
Aldeyra resubmits dry eye treatment NDA to FDA By Investing.com - Investing.com Australia
Aldeyra Therapeutics Files Again for FDA OK of Dry-Eye Disease Treatment - MarketWatch
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease - StockTitan
Aldeyra Therapeutics extends loan agreement terms - Investing.com India
Aldeyra Therapeutics extends loan agreement terms By Investing.com - Investing.com UK
Aldeyra Therapeutics, Inc. Enters into the Fourth Amendment to Loan and Security Agreement - Marketscreener.com
Aldeyra shares hold Outperform rating on pipeline progress By Investing.com - Investing.com Canada
What was Aldeyra Therapeutics Inc (ALDX)’s performance in the last session? - US Post News
Aldeyra Therapeutics Inc (ALDX) rating upgrades by Oppenheimer - Knox Daily
Market Watch Highlights: Aldeyra Therapeutics Inc (ALDX) Ends on an Upturn Note at 5.50 - The Dwinnex
Aldeyra Therapeutics Inc (ALDX) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Perceptive Advisors LLC Buys 682,265 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
(ALDX) Trading Signals - Stock Traders Daily
Market Highlights: Aldeyra Therapeutics Inc (ALDX) Ends on a High Note at 5.65 - The Dwinnex
What technical indicators reveal about ALDX stock - US Post News
Bank of New York Mellon Corp Has $648,000 Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Insider Sale Alert: Aldeyra Therapeutics Inc [ALDX] – Is it Time to sell? - Knox Daily
Get in on Aldeyra Therapeutics Inc’s (ALDX) buy-in window today! - SETE News
Federated Hermes Inc. Takes Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
Federated Hermes Inc. Invests $1.76 Million in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra To Make Second Bid For FDA Approval Of Dry Eye Disease Drug - RTTNews
Los Angeles Capital Management LLC Decreases Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Oppenheimer Upgrades Aldeyra Therapeutics Inc (ALDX) to an Outperform from a Perform - Knox Daily
PFG Investments LLC Purchases Shares of 396,247 Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
ALDX Stock Sees Surge of Approximately 20.38% in Last Five Days - Knox Daily
There is no doubt that Aldeyra Therapeutics Inc (ALDX) ticks all the boxes. - SETE News
Metric Deep Dive: Understanding Aldeyra Therapeutics Inc (ALDX) Through its Ratios - The Dwinnex
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
High Growth Tech Stocks To Watch In The United States - Simply Wall St
Aldeyra Therapeutics Inc (ALDX) requires closer examination - US Post News
Aldeyra Therapeutics appoints new financial officer - Investing.com India
Aldeyra Therapeutics appoints new financial officer By Investing.com - Investing.com Canada
Aldeyra Therapeutics Announces Executive Team Changes - TipRanks
Aldeyra Therapeutics Inc Inc. (ALDX) Price Performance: The Impact of Insider Trading and Institutional Holdings - The InvestChronicle
Finanzdaten der Aldeyra Therapeutics Inc-Aktie (ALDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):